Of note, YAP1 may be of interest as a therapeutic target because pharmacologic inhibition of YAP/TAZ dependent transcription has shown efficiency in pre-clinical studies of different cancer types including glioblastoma [15, 45]. The gene discussed is YAP1; the disease is glioblastoma.